
    
      All drugs used in this study have been used in the prevention of graft-versus-host-disease
      after allogeneic hematopoietic cell transplant. Tacrolimus and Methotrexate used in
      combination are currently used as standard of care in the prevention of
      graft-versus-host-disease after allogeneic hematopoietic cell transplant. Tacrolimus and
      Rapamycin is a newer combination we are testing to see if it would be better than Tacrolimus
      and Methotrexate.
    
  